Blood Purification Equipment - Medical Devices Pipeline Assessment, 2018

  • ID: 4592044
  • Report
  • 171 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Accel Diagnostics LLC
  • Cerus Corp
  • Ex Vivo Dynamics Inc
  • Immunicom Inc
  • NxStage Medical Inc
  • ProSorp BioTech Inc
  • MORE
Blood Purification Equipment - Medical Devices Pipeline Assessment, 2018

Summary

The author's Medical Devices sector report, “Blood Purification Equipment - Medical Devices Pipeline Assessment, 2018" provides an overview of Blood Purification Equipment currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Blood Purification Equipment pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Blood Purification Equipment under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Blood Purification Equipment and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry.
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Blood Purification Equipment under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Accel Diagnostics LLC
  • Cerus Corp
  • Ex Vivo Dynamics Inc
  • Immunicom Inc
  • NxStage Medical Inc
  • ProSorp BioTech Inc
  • MORE
1 Table of Contents

2 Introduction
2.1 Blood Purification Equipment Overview

3 Products under Development
3.1 Blood Purification Equipment - Pipeline Products by Stage of Development
3.2 Blood Purification Equipment - Pipeline Products by Territory
3.3 Blood Purification Equipment - Pipeline Products by Regulatory Path
3.4 Blood Purification Equipment - Pipeline Products by Estimated Approval Date
3.5 Blood Purification Equipment - Ongoing Clinical Trials

4 Blood Purification Equipment - Pipeline Products under Development by Companies
4.1 Blood Purification Equipment Companies - Pipeline Products by Stage of Development
4.2 Blood Purification Equipment - Pipeline Products by Stage of Development

5 Blood Purification Equipment Companies and Product Overview
5.1 Accel Diagnostics LLC Company Overview
5.2 Aethlon Medical Inc Company Overview
5.3 Cerus Corp Company Overview
5.4 Children's Hospital Boston Company Overview
5.5 CytoSorbents Corp Company Overview
5.6 Ex Vivo Dynamics Inc Company Overview
5.7 Good SIRS Company Overview
5.8 Immunicom Inc Company Overview
5.9 McGowan Institute for Regenerative Medicine Company Overview
5.10 Mediseive Ltd Company Overview
5.11 NxStage Medical Inc Company Overview
5.12 Opsonix Inc Company Overview
5.13 ProSorp BioTech Inc Company Overview
5.14 Spectral Medical Inc Company Overview
5.15 Toray Medical Co Ltd Company Overview
5.16 Zata Pharmaceuticals Inc Company Overview

6 Blood Purification Equipment- Recent Developments
6.1 Jun 15, 2018: Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association
6.2 Jun 12, 2018: CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility
6.3 Jun 08, 2018: Aethlon Medical Reports Fiscal 2018 Financial Results
6.4 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value
6.5 Jun 01, 2018: Cerus Announces Presentations Highlighting INTERCEPT Blood Systems at the 35th International Congress of the International Society of Blood Transfusion
6.6 May 30, 2018: Spectral Provides Corporate Update
6.7 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
6.8 May 21, 2018: Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference
6.9 May 16, 2018: Cerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells
6.10 May 14, 2018: Immunicom's Immunotherapy Product Receives U.S. FDA Breakthrough Device Designation for the Treatment of Cancer
6.11 May 14, 2018: CytoSorb Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use
6.12 May 11, 2018: Spectral Announces First Quarter 2018 Results
6.13 May 08, 2018: Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief Technology Officer
6.14 May 08, 2018: CytoSorbents Reports Strong First Quarter 2018 Financial Results
6.15 May 08, 2018: Cerus Reports First Quarter 2018 Results
6.16 May 08, 2018: Haemonetics Reports 4th Quarter and Fiscal Year 2018 Results and Provides Fiscal 2019 Guidance
6.17 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy
6.18 May 02, 2018: Biocon Regulatory Audit Update
6.19 Apr 26, 2018: Baxter Reports First-Quarter 2018 Results And Increases Financial Outlook For Full-Year 2018
6.20 Apr 26, 2018: Golden Meditech: Re-designation of Directors and Changes of Members of Board Committees
6.21 Apr 26, 2018: Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr[TOPC : Pharma - Biocon Ltd]
6.22 Apr 25, 2018: Cerus Announces Health Canada Approval of the INTERCEPT Blood System for Platelets
6.23 Apr 24, 2018: CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb During Complex Cardiac Surgery
6.24 Apr 16, 2018: Golden Meditech's Associate, Cellenkos Appoints Alick Sun as Corporate & Business Development SVP
6.25 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics
6.26 Apr 02, 2018: Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.
6.27 Mar 29, 2018: Spectral Announces Fourth Quarter and Fiscal 2017 Results
6.28 Mar 19, 2018: US Food and Drug Administration (FDA) provides communication to Spectral
6.29 Mar 19, 2018: ExThera Medical Announces Creation of European Subsidiary
6.30 Mar 13, 2018: Cerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center Customer
6.31 Mar 08, 2018: CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017
6.32 Mar 08, 2018: Cerus Reports Fourth Quarter And Year End 2017 Financial Results
6.33 Feb 26, 2018: Robert Ward, CEO of ExThera Medical, Elected to Prestigious National Academy of Engineering
6.34 Feb 15, 2018: Study Shows Computer-Guided Insulin Dosing Plus More Frequent Blood Glucose Testing Leads to Better Outcomes for Patients with Diabetes
6.35 Feb 06, 2018: CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference
6.36 Feb 06, 2018: Haemonetics 3rd Quarter Fiscal 2018 Earnings
6.37 Feb 05, 2018: MedaPhor Group: Innovate UK grant award confirmed
6.38 Feb 01, 2018: New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb Blood Purification
6.39 Feb 01, 2018: Spectral Medical Announces the Appointment of Chief Financial Officer
6.40 Feb 01, 2018: Baxter Reports 2017 Fourth-Quarter and Full-Year Results
6.41 Feb 01, 2018: Aethlon Medical Announces Fiscal 2018 Third Quarter Results
6.42 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
6.43 Jan 25, 2018: Ellen M. Zane Rejoins Haemonetics Board of Directors
6.44 Jan 23, 2018: Cerus Reports Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells in Thalassemia Patients
6.45 Jan 23, 2018: Aethlon Medical Announces Validation Completion for European Patent Protecting Methods of Quantifying Exosomes
6.46 Jan 18, 2018: Aethlon Medical Announces Allowance of U.S. Patent that Broadens Protection for the Aethlon Hemopurifier to Treat Viral Infections
6.47 Jan 10, 2018: Sabrina Martucci Johnson Joins Aethlon Medical's Board of Directors
6.48 Jan 08, 2018: CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter
6.49 Jan 08, 2018: Cerus Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017

7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Blood Purification Equipment - Pipeline Products by Stage of Development
Table 2: Blood Purification Equipment - Pipeline Products by Territory
Table 3: Blood Purification Equipment - Pipeline Products by Regulatory Path
Table 4: Blood Purification Equipment - Pipeline Products by Estimated Approval Date
Table 5: Blood Purification Equipment - Ongoing Clinical Trials
Table 6: Blood Purification Equipment Companies - Pipeline Products by Stage of Development
Table 7: Blood Purification Equipment - Pipeline Products by Stage of Development
Table 8: Accel Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 9: mPharesis - Product Status
Table 10: mPharesis - Product Description
Table 11: Aethlon Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: ASEPSYS Device - Product Status
Table 13: ASEPSYS Device - Product Description
Table 14: Hemopurifier - Product Status
Table 15: Hemopurifier - Product Description
Table 16: Aethlon Medical Inc - Ongoing Clinical Trials Overview
Table 17: Hemopurifier - Plasma Exosome Concentration in Cancer Patients Undergoing Treatment
Table 18: Hemopurifier - Sepsis-related Virus Study of Aethlon Hemopurifier
Table 19: Cerus Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 20: INTERCEPT Blood System - Platelets - Product Status
Table 21: INTERCEPT Blood System - Platelets - Product Description
Table 22: INTERCEPT Blood System - Red Blood Cells - Product Status
Table 23: INTERCEPT Blood System - Red Blood Cells - Product Description
Table 24: INTERCEPT Blood System - Zika Virus - Product Status
Table 25: INTERCEPT Blood System - Zika Virus - Product Description
Table 26: Cerus Corp - Ongoing Clinical Trials Overview
Table 27: INTERCEPT Blood System - Platelets - A Randomized, Double-Blind, Phase I, Dose-escalation Study for the Safety of Whole Blood Treated with Amustaline (S-303) and Glutathione (GSH), a Pathogen Inactivation System, and Transfused to Anemic Adult Cancer Patients
Table 28: INTERCEPT Blood System - Red Blood Cells - A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion
Table 29: INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections (RedeS Study) and Treatment Use Open-label Extension Study
Table 30: INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-Blind, Phase I, Dose-escalation Study for the Safety of Whole Blood Treated with Amustaline (S-303) and Glutathione (GSH), a Pathogen Inactivation System, and Transfused to Anemic Adult Cancer Patients
Table 31: INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients undergoing Complex Cardiac Surgery Procedures
Table 32: INTERCEPT Blood System - Red Blood Cells - Measurement of the Recovery and Lifespan of Red Blood Cells from Pathogen-reduced, Stored Blood Units Using Cellular Biotinylation
Table 33: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Immune-Modulating Extracorporeal Circuit - Product Status
Table 35: Immune-Modulating Extracorporeal Circuit - Product Description
Table 36: CytoSorbents Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 37: BetaSorb - Product Status
Table 38: BetaSorb - Product Description
Table 39: ContrastSorb - Product Status
Table 40: ContrastSorb - Product Description
Table 41: CST 301 - Product Status
Table 42: CST 301 - Product Description
Table 43: CytoSorb - Product Status
Table 44: CytoSorb - Product Description
Table 45: CytoSorb-XL - Product Status
Table 46: CytoSorb-XL - Product Description
Table 47: DrugSorb - Product Status
Table 48: DrugSorb - Product Description
Table 49: HemoDefend - Product Status
Table 50: HemoDefend - Product Description
Table 51: CytoSorbents Corp - Ongoing Clinical Trials Overview
Table 52: CytoSorb - Case-observation and Compassionate Use: Use of Extracorporeal Treatment with the Cytosorb-Adsorber for the Reduction of Postoperative Hyperinflammation and SIRS After Heart-surgery with the Use of a Heart-lung-machine
Table 53: CytoSorb - Cytokine Adsorption in Sepsis and Acute Kidney Injury
Table 54: CytoSorb - Elimination of Antibiotics During Combined Continuous Renal Replacement Therapy and Cytosorb Adsorptive Therapy in Patients with Sepsis and Acute Kidney Injury
Table 55: CytoSorb - Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy - A Randomized Study : EXCESS
Table 56: CytoSorb - Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients with Rhabdomyolysis
Table 57: CytoSorb - Hemoadsorption with CytoSorb in Post-Cardiac Arrest Syndrome: a Pilot Study (The CATCH Trial: Post Cardiac Arrest Therapy with Cytosorb Hemoadsorption)
Table 58: CytoSorb - Immunomodulatory Effect of Extracorporeal Cytokine Adsorption in Cardiac Surgery
Table 59: CytoSorb - International Registry on the Use of the CytoSorb-Adsorber in ICU Patients
Table 60: CytoSorb - Myeloid-derived Supressor Cells in Uncomplicated Versus Complicated Patients after Cardiac Surgery
Table 61: CytoSorb - Pancreatitis CytoSorbents (CytoSorb) Inflammatory Cytokine Removal: A Prospective Study
Table 62: CytoSorb - Removal of Cytokine on Cardiopulmonary Bypass with CytoSorb Compared to on- and Off-pump Myocardial Revascularization
Table 63: CytoSorb - Removal of Cytokines During Cardiac Surgery
Table 64: CytoSorb - Removal of Cytokines in Patients Undergoing Cardiac Surgery with CPB (The REMOTE Study)
Table 65: CytoSorb - Revealing Mechanisms and Investigating Efficacy of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients with Infective Endocarditis - A Multicentric Randomized Controlled Group Sequential Trial
Table 66: CytoSorb - The Impact of Pre-emptive Intraoperative Use of Extracorporeal Cytokine Adsorption during Orthotopic Heart Transplantation
Table 67: Ex Vivo Dynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 68: BloodGuard - Product Status
Table 69: BloodGuard - Product Description
Table 70: Good SIRS Pipeline Products & Ongoing Clinical Trials Overview
Table 71: Blood-Filtering Device - Product Status
Table 72: Blood-Filtering Device - Product Description
Table 73: Immunicom Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 74: Immunopheresis Blood-Filtering Device - Product Status
Table 75: Immunopheresis Blood-Filtering Device - Product Description
Table 76: McGowan Institute for Regenerative Medicine Pipeline Products & Ongoing Clinical Trials Overview
Table 77: Hemoadsorption Device - Sepsis - Product Status
Table 78: Hemoadsorption Device - Sepsis - Product Description
Table 79: Mediseive Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 80: Magnetic Blood Filtration Device - Leukaemia - Product Status
Table 81: Magnetic Blood Filtration Device - Leukaemia - Product Description
Table 82: Magnetic Blood Filtration Device - Malaria - Product Status
Table 83: Magnetic Blood Filtration Device - Malaria - Product Description
Table 84: Magnetic Blood Filtration Device - Sepsis - Product Status
Table 85: Magnetic Blood Filtration Device - Sepsis - Product Description
Table 86: NxStage Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 87: DLT Device - Sepsis - Product Status
Table 88: DLT Device - Sepsis - Product Description
Table 89: Opsonix Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 90: Pathogen-Extracting Therapy Device - Product Status
Table 91: Pathogen-Extracting Therapy Device - Product Description
Table 92: ProSorp BioTech Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 93: Blood Perfusion Device - Product Status
Table 94: Blood Perfusion Device - Product Description
Table 95: Spectral Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 96: Toraymyxin PMX-20R - Product Status
Table 97: Toraymyxin PMX-20R - Product Description
Table 98: Spectral Medical Inc - Ongoing Clinical Trials Overview
Table 99: Toraymyxin PMX-20R - Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract Infection: A Single-arm Clinical Trial
Table 100: Toraymyxin PMX-20R - The Effect of Endotoxin Adsorber Hemoperfusion on the Microcirculation in Patients with Severe Sepsis and Septic Shock
Table 101: Toray Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 102: Toray Leukocyte Removal Column - Product Status
Table 103: Toray Leukocyte Removal Column - Product Description
Table 104: Zata Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 105: Anti - Pathogen Device - Product Status
Table 106: Anti - Pathogen Device - Product Description
Table 107: Glossary

List of Figures
Figure 1: Blood Purification Equipment - Pipeline Products by Stage of Development
Figure 2: Blood Purification Equipment - Pipeline Products by Territory
Figure 3: Blood Purification Equipment - Pipeline Products by Regulatory Path
Figure 4: Blood Purification Equipment - Pipeline Products by Estimated Approval Date
Figure 5: Blood Purification Equipment - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Accel Diagnostics LLC
  • Aethlon Medical Inc
  • Cerus Corp
  • Children's Hospital Boston
  • CytoSorbents Corp
  • Ex Vivo Dynamics Inc
  • Good SIRS
  • Immunicom Inc
  • McGowan Institute for Regenerative Medicine
  • Mediseive Ltd
  • NxStage Medical Inc
  • Opsonix Inc
  • ProSorp BioTech Inc
  • Spectral Medical Inc
  • Toray Medical Co Ltd
  • Zata Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll